Variation in Single Gene May Determine Response to Humira in IBD Patients, Study Reports

Variation in Single Gene May Determine Response to Humira in IBD Patients, Study Reports
A single variation in the DNA sequence of a particular gene, called ATG16L1, was associated with response to Humira (adalimumab) treatment in a group of people with inflammatory bowel disease (IBD), a disease in which genetics is known to play a role and newer therapies have had a somewhat mixed response. Humira, with Remicade (infliximab), is an anti-tumor necrosis factor-alpha (anti-TNFα) known to be capable of inducing and maintaining remission in certain IBD cases, but "are not effective in 20–40% of IBD patients and loss of response and/or is seen in a substantial proportion of the patients," the researchers wrote. Their study “
Subscribe or to access all post and page content.